• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    1/25/23 8:05:59 AM ET
    $ARDS
    $AXLA
    $BXRX
    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARDS alert in real time by email

    Gainers

    • Sonoma Pharmaceuticals (NASDAQ:SNOA) stock rose 80.0% to $2.16 during Wednesday's pre-market session. The company's market cap stands at $6.7 million.
    • First Wave BioPharma (NASDAQ:FWBI) stock moved upwards by 28.05% to $5.66. The market value of their outstanding shares is at $5.6 million.
    • Incannex Healthcare (NASDAQ:IXHL) stock increased by 23.74% to $3.96. The company's market cap stands at $241.3 million.
    • Aridis Pharmaceuticals (NASDAQ:ARDS) shares increased by 17.85% to $0.99. The market value of their outstanding shares is at $25.7 million.
    • INmune Bio (NASDAQ:INMB) shares moved upwards by 17.33% to $8.8. The company's market cap stands at $157.9 million.
    • Creative Medical Tech (NASDAQ:CELZ) stock increased by 13.72% to $0.58. The market value of their outstanding shares is at $8.1 million.

    Losers

    • Axcella Health (NASDAQ:AXLA) stock decreased by 23.3% to $0.46 during Wednesday's pre-market session. The company's market cap stands at $33.8 million.
    • Precigen (NASDAQ:PGEN) shares declined by 17.36% to $1.81. The market value of their outstanding shares is at $376.7 million.
    • Finch Therapeutics Group (NASDAQ:FNCH) stock declined by 17.16% to $0.41. The market value of their outstanding shares is at $19.6 million.
    • Calithera Biosciences (NASDAQ:CALA) shares fell 13.47% to $0.4. The company's market cap stands at $1.9 million.
    • Baudax Bio (NASDAQ:BXRX) stock fell 10.79% to $3.72. The market value of their outstanding shares is at $2.0 million.
    • Intuitive Surgical (NASDAQ:ISRG) shares declined by 8.91% to $235.0. The market value of their outstanding shares is at $83.0 billion. As per the press release, Q4 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ARDS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARDS
    $AXLA
    $BXRX
    $CALA

    CompanyDatePrice TargetRatingAnalyst
    Intuitive Surgical Inc.
    $ISRG
    3/11/2026$590.00Neutral → Buy
    Citigroup
    Intuitive Surgical Inc.
    $ISRG
    1/27/2026$660.00Buy
    TD Cowen
    Intuitive Surgical Inc.
    $ISRG
    12/11/2025$635.00Buy → Neutral
    Citigroup
    Precigen Inc.
    $PGEN
    8/15/2025Underweight → Neutral
    Analyst
    Intuitive Surgical Inc.
    $ISRG
    7/23/2025Buy → Hold
    Erste Group
    INmune Bio Inc.
    $INMB
    7/1/2025$0.60Sector Outperform → Sector Underperform
    Scotiabank
    INmune Bio Inc.
    $INMB
    7/1/2025Buy → Neutral
    BTIG Research
    Intuitive Surgical Inc.
    $ISRG
    6/9/2025$440.00Hold → Sell
    Deutsche Bank
    More analyst ratings

    $ARDS
    $AXLA
    $BXRX
    $CALA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25

    GERMANTOWN, Md., March 11, 2026 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release full year 2025 financial results and provide business updates on Wednesday, March 25, 2026. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in

    3/11/26 4:05:00 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intuitive Expands Investment and Footprint in Europe

    SUNNYVALE, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the completion of its acquisition of the da Vinci and Ion distribution business operated by ab medica, Abex, Excelencia Robótica, and their affiliates. The completion marks the formal expansion of Intuitive's direct operations in Europe, enabling the company to support customers in a more agile and integrated way, and bring minimally invasive care to more patients across Italy, Spain, Portugal, Malta, San Marino and associated territories. "Today marks an important step in our commitment to expand

    3/2/26 7:00:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    Incannex Announces Reverse Stock Split

    MELBOURNE, Australia and NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, today announced that the board of directors of the Company approved a 1-for-30 reverse stock split (the "Reverse Split") of the Company's common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on May 27, 2025. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on February 26, 2026. The Company's common stock will open for trading under a new CUSIP numb

    2/25/26 9:20:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDS
    $AXLA
    $BXRX
    $CALA
    SEC Filings

    View All

    SEC Form 144 filed by Intuitive Surgical Inc.

    144 - INTUITIVE SURGICAL INC (0001035267) (Subject)

    3/4/26 4:43:23 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    Intuitive Surgical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - INTUITIVE SURGICAL INC (0001035267) (Filer)

    3/2/26 5:13:42 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    SEC Form 144 filed by Intuitive Surgical Inc.

    144 - INTUITIVE SURGICAL INC (0001035267) (Subject)

    2/27/26 4:11:48 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ARDS
    $AXLA
    $BXRX
    $CALA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intuitive Surgical upgraded by Citigroup with a new price target

    Citigroup upgraded Intuitive Surgical from Neutral to Buy and set a new price target of $590.00

    3/11/26 8:28:54 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    TD Cowen initiated coverage on Intuitive Surgical with a new price target

    TD Cowen initiated coverage of Intuitive Surgical with a rating of Buy and set a new price target of $660.00

    1/27/26 8:46:58 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    Intuitive Surgical downgraded by Citigroup with a new price target

    Citigroup downgraded Intuitive Surgical from Buy to Neutral and set a new price target of $635.00

    12/11/25 8:53:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ARDS
    $AXLA
    $BXRX
    $CALA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Medical Officer Curet Myriam exercised 105 shares at a strike of $229.39 and sold $51,865 worth of shares (105 units at $493.95) (SEC Form 4)

    4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

    3/11/26 1:46:06 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    SVP & Chief Mfg and Supply Cha Brosius Mark sold $630,475 worth of shares (1,293 units at $487.61), decreasing direct ownership by 44% to 1,613 units (SEC Form 4)

    4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

    3/10/26 2:24:12 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    SVP & Chief Mfg and Supply Cha Brosius Mark sold $1,815,062 worth of shares (3,658 units at $496.19), decreasing direct ownership by 56% to 2,906 units (SEC Form 4)

    4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

    3/5/26 6:38:35 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ARDS
    $AXLA
    $BXRX
    $CALA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Shah Rutul R bought $6,800 worth of shares (2,000 units at $3.40), increasing direct ownership by 0.50% to 405,959 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/30/25 4:07:27 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Tennant Phil bought $21,480 worth of shares (6,000 units at $3.58), increasing direct ownership by 10% to 65,031 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/30/25 4:04:51 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Thomasian Harry Jr. bought $40,016 worth of shares (11,216 units at $3.57), increasing direct ownership by 2% to 468,626 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/26/25 5:01:54 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDS
    $AXLA
    $BXRX
    $CALA
    Leadership Updates

    Live Leadership Updates

    View All

    Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board

    MELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board ("CAB"): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB was formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. The addition of Drs. Stein, Cutler, and Kalali further strengthens the Board's expertise across psychiatry, neurobiology, psychopharmacology, an

    1/29/26 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intel Appoints Dr. Craig H. Barratt to Board of Directors

    Intel Corporation (NASDAQ:INTC) today announced that Craig H. Barratt, Ph.D., 63, has been appointed to its board of directors, effective immediately. Dr. Barratt will serve as an independent director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110908011/en/Dr. Craig H. Barratt joins Intel's board as an independent director. "Craig is a highly accomplished technology leader with a proven ability to innovate, scale, and transform businesses," said Lip-Bu Tan, Intel CEO. "He is a seasoned semiconductor executive with experience at multiple leading-edge technology companies, which will be invaluable as we continue to execute

    11/10/25 6:21:00 PM ET
    $ALAB
    $INTC
    $ISRG
    Semiconductors
    Technology
    Industrial Specialties
    Health Care

    Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

    NEW YORK and MELBOURNE, Australia, July 25, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the appointment of Charlene E. Gamaldo, M.D. to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board. Incannex Chief Medical Officer Dr. Lou Barbato commented:"We are fortunate to welcome Dr. Gamaldo to the Incannex Clinical Advisory Board. Her leadership across neurology, psychiatry, and public health, combined with a distinguished track record in sleep medicine, brings tremendous value to our obstructive sleep apnea prog

    7/25/25 7:30:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDS
    $AXLA
    $BXRX
    $CALA
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Breaking: Stock Acquired at INmune Bio Inc. on Jun 26

    Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

    6/26/24 2:54:12 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARDS
    $AXLA
    $BXRX
    $CALA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aridis Pharmaceuticals Inc.

    SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)

    11/14/24 4:46:40 PM ET
    $ARDS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by INmune Bio Inc.

    SC 13G - Inmune Bio, Inc. (0001711754) (Subject)

    10/25/24 10:15:45 AM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by INmune Bio Inc.

    SC 13G/A - Inmune Bio, Inc. (0001711754) (Subject)

    10/2/24 4:50:56 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARDS
    $AXLA
    $BXRX
    $CALA
    Financials

    Live finance-specific insights

    View All

    Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25

    GERMANTOWN, Md., March 11, 2026 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release full year 2025 financial results and provide business updates on Wednesday, March 25, 2026. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in

    3/11/26 4:05:00 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intuitive Announces Fourth Quarter Earnings

    SUNNYVALE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended December 31, 2025. Q4 Highlights Worldwide procedures (da Vinci and Ion combined) grew approximately 18% compared with the fourth quarter of 2024. Da Vinci procedures grew approximately 17% and Ion procedures grew approximately 44%.The Company placed 532 da Vinci surgical systems, compared with 493 in the fourth quarter of 2024. The fourth quarter 2025 da Vinci surgical system placements included 303 da Vinci 5 systems, compared with 174 i

    1/22/26 4:05:00 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    Intuitive Announces Preliminary Fourth Quarter and Full Year 2025 Results

    SUNNYVALE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2025 financial results ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. Financial and Operational Highlights Fourth quarter 2025 worldwide procedures (da Vinci and Ion combined) grew approximately 18% compared with the fourth quarter of 2024. Da Vinci procedures grew approximately 17% and Ion procedures grew approximately 44%. Average da Vinci system utilization increased 4%

    1/14/26 9:05:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care